Related Experiment Video
Updated: Jul 13, 2026

Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
Probiotics in infectious diarrhoea in children: are they indicated?
Y Vandenplas1, S Salvatore, M Vieira
1Universitair Ziekenhuis Brussel Junior, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium. yvanvandenplas@az.vub.ac.be
Insights
Probiotics can shorten infectious gastroenteritis duration by about 24 hours, offering moderate clinical benefits. Specific strains like Lactobacillus and Saccharomyces boulardii show efficacy, but clinical relevance is limited.
Area of Science:
- Gastroenterology
- Microbiology
- Pharmacology
Background:
- Infectious gastroenteritis is a major global health issue, with oral rehydration as the primary treatment.
- Probiotics, once considered alternative medicine, are now recognized for their potential in mainstream medical practice.
- Some probiotic strains have demonstrated a reduction in infectious gastroenteritis severity and duration.
Purpose of the Study:
- To evaluate the efficacy of probiotics as an add-on therapy for acute infectious gastroenteritis.
- To assess the clinical relevance and potential benefits of probiotic use in gastroenteritis treatment.
- To identify specific probiotic strains with proven clinical efficacy.
Main Methods:
- Review of clinical studies on probiotic use in infectious gastroenteritis.
- Analysis of evidence for specific probiotic strains, including Lactobacilli and Saccharomyces boulardii.
- Assessment of strain-specific mechanisms of action and safety profiles.
Main Results:
- Certain probiotic strains, such as Lactobacillus casei GG, Lactobacillus reuteri, and Saccharomyces boulardii, show efficacy in reducing gastroenteritis duration.
- Evidence for efficacy is stronger in viral gastroenteritis compared to bacterial or parasitic infections.
- Probiotics offer a statistically significant, though clinically moderate, benefit in shortening diarrhea duration.
Conclusions:
- Selected probiotic strains can be a beneficial add-on therapy for acute infectious gastroenteritis.
- Strain specificity and evidence of clinical efficacy are crucial for recommending probiotics.
- While generally safe, rare side effects necessitate caution in high-risk individuals.
Abstract:
Infectious gastroenteritis continues to be a leading cause of mortality and morbidity worldwide. The cornerstone of treatment remains replacement of water and electrolyte losses with oral rehydration solution. Until a few years ago, probiotics were discussed primarily in the context of alternative medicine, but they are now entering mainstream medical practice since a decrease of the severity and duration of infectious gastroenteritis in approximately 24 hours has been shown for some strains. Therefore, probiotics are a potential add-on therapy in acute gastro-enteritis. The shortening of the duration of diarrhoea and the reduction in hospital stay result in a social and economic benefit. Evidence found in viral gastroenteritis is more convincing than in bacterial or parasitic infection. Mechanisms of action are strain specific and only those commercial products for which there is evidence of clinical efficacy should be recommended. Timing of administration is also of importance. In acute gastroenteritis, there is evidence for efficacy of some strains of lactobacilli (e.g. Lactobacillus caseii GG and Lactobacillus reuteri) and for Saccharomyces boulardii. Probiotics are "generally regarded as safe", but side effects such as septicaemia and fungaemia have very rarely been reported in high-risk situations. Although most studies conclude in a statistically significant shortening of the duration of diarrhea, the clinical relevance of this finding is limited. In conclusion, selected strains of probiotics result in a statistically significant but clinically moderate benefit in shortening the duration of diarrhoea caused by acute infectious gastroenteritis.
Related Concept Videos
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Probiotics
Microbiota Modulation by Antibiotics
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Development of Human Microbiota
